Drug class review : final update 5 report, Second-generation antidepressants

Resource Information

The work Drug class review : final update 5 report, Second-generation antidepressants represents a distinct intellectual or artistic creation found in Boston University Libraries. This resource is a combination of several types including: Work, Language Material, Books.

Label

Drug class review : final update 5 report, Second-generation antidepressants

Title remainder

final update 5 report

Title part

Second-generation antidepressants

Statement of responsibility

Gerald Gartlehner ... [et al.] ; produced by RTI-UNC Evidence-based Practice Center, Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill

Title variation

Second-generation antidepressants

Contributor

• Drug Effectiveness Review Project
• Oregon Health & Science University
• Cecil G. Sheps Center for Health Services Research
• Research Triangle Institute-University of North Carolina at Chapel Hill Evidence-based Practice Center
• Gartlehner, Gerald
• Oregon Health & Science University, Evidence-based Practice Center

Subject

• Antidepressive Agents, Second-Generation -- adverse effects
• Antidepressive Agents, Second-Generation -- therapeutic use
• Review
• Serotonin Uptake Inhibitors -- adverse effects
• Serotonin Uptake Inhibitors -- therapeutic use

Genre

• Review

Language

• eng
• eng

Summary

PURPOSE: We compared the effectiveness and harms of second-generation antidepressants in the treatment of major depressive disorder (MDD), dysthymia, subsyndromal depression, seasonal affective disorder, generalized anxiety disorder, obsessive compulsive disorder, panic disorder, post-traumatic stress disorder, social anxiety disorder, and premenstrual dysphoric disorder. DATA SOURCES: We searched PubMed, Embase, PsycINFO, the Cochrane Library, and the International Pharmaceutical Abstracts until September 2010. For additional data we also hand searched reference lists, US Food and Drug Administration medical and statistical reviews and dossiers submitted by pharmaceutical companies. REVIEW METHODS: Study selection, data abstraction, validity assessment, grading the strength of the evidence, and data synthesis were all carried out according to standard Drug Effectiveness Review Project review methods. RESULTS AND CONCLUSIONS: Overall, we found no substantial differences in comparative efficacy and effectiveness of second-generation antidepressants for the treatment of depressive or anxiety disorders. Differences exist in the incidence of specific adverse events and the onset of action. Except for MDD, the evidence is limited to few direct comparisons for most indications. No head-to-head evidence is available for MDD in pediatric populations, dysthymia, subsyndromal depression, seasonal affective disorder, and premenstrual dysphoric disorder

Member of

• Drug class reviews

Cataloging source

DNLM

Funding information

Funding: The Drug Effectiveness Review Project, composed of 12 organizations including 11 state Medicaid agencies, and the Canadian Agency for Drugs and Technology in Health commissioned and funded for this report. These organizations selected the topic of the report and had input into its Key Questions. The content and conclusions of the report were entirely determined by the Evidence-based Practice Center researchers. The authors of this report have no financial interest in any company that makes or distributes the products reviewed in this report.

Illustrations

illustrations

Index

no index present

Literary form

non fiction

Nature of contents

• dictionaries
• surveys of literature

NLM call number

QV 77.5

Series statement

Drug class reviews